Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

<strong>Background:</strong> Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. <strong&g...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Westwood, S, Baird, AL, Hye, A, Ashton, NJ, Nevado-Holgado, AJ, Anand, SN, Liu, B, Newby, D, Bazenet, C, Kiddle, SJ, Ward, M, Newton, B, Desai, K, Hehir, C, Zanette, M, Galimberti, D, Parnetti, L, Lleó, A, Baker, S, Narayan, VA, Van Der Flier, WM, Scheltens, P, Teunissen, CE, Visser, PJ, Lovestone, S
Natura:	Journal article
Pubblicazione:	Frontiers Media 2018

Documenti analoghi

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
di: Sarah Westwood, et al.
Pubblicazione: (2018-12-01)

The influence of insulin resistance on CSF and plasma biomarkers of Alzheimer’s pathology
di: Westwood, S, et al.
Pubblicazione: (2017)

New CSF biomarkers on the block
di: Charlotte E Teunissen, et al.
Pubblicazione: (2016-09-01)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
di: Rosha Babapour Mofrad, et al.
Pubblicazione: (2019-12-01)

Determining the molecular pathways underlying the protective effect of non-steroidal anti-inflammatory drugs for Alzheimer's disease: A bioinformatics approach
di: Nevado-Holgado, A, et al.
Pubblicazione: (2016)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
di: Eleonora M. Vromen, et al.
Pubblicazione: (2022-01-01)

Blood-based proteomic biomarkers of Alzheimer’s disease pathology
di: Baird, A, et al.
Pubblicazione: (2015)

Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach
di: Alejo J Nevado-Holgado, et al.
Pubblicazione: (2017-01-01)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
di: Betty Marije Tijms, et al.
Pubblicazione: (2021-08-01)

Establishing cutoff values for visual amyloid positivity in [18F]flutemetamol PET
di: Yong-Jin Park, et al.
Pubblicazione: (2025-01-01)

Amyloid-Targeting PET Tracer [18F]Flutemetamol Accumulates in Atherosclerotic Plaques
di: Sanna Hellberg, et al.
Pubblicazione: (2019-03-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
di: Teunissen, C, et al.
Pubblicazione: (2018)

Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
di: Lyduine E. Collij, et al.
Pubblicazione: (2023-11-01)

Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET
di: Si Eun Kim, et al.
Pubblicazione: (2020-01-01)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
di: Eline A. J. Willemse, et al.
Pubblicazione: (2021-01-01)

Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice.
di: Stephanie J B Vos, et al.
Pubblicazione: (2014-01-01)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
di: Yanaika S. Hok‐A‐Hin, et al.
Pubblicazione: (2023-07-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer's disease
di: Winchester, L, et al.
Pubblicazione: (2018)

Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods
di: Mark R. Battle, et al.
Pubblicazione: (2018-12-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
di: Charlotte E. Teunissen, et al.
Pubblicazione: (2018-03-01)

Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.
di: Vandenberghe, R, et al.
Pubblicazione: (2013)

Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated
di: Young-Sil An, et al.
Pubblicazione: (2021-06-01)

Temporal and anatomical distribution of 18F-flutemetamol uptake in canine brain using positron emission tomography
di: Taesik Yun, et al.
Pubblicazione: (2020-01-01)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
di: Juhan Reimand, et al.
Pubblicazione: (2019-12-01)

Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly
di: Westwood, S, et al.
Pubblicazione: (2016)

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
di: Vandenberghe, R, et al.
Pubblicazione: (2010)

Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment
di: Hugh G. Pemberton, et al.
Pubblicazione: (2023-05-01)

Automatic lesion detection and segmentation in 18F-flutemetamol positron emission tomography images using deep learning
di: Chan Ju Ryu
Pubblicazione: (2022-12-01)

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
di: Fiona Heeman, et al.
Pubblicazione: (2019-03-01)

Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank
di: Cullen, B, et al.
Pubblicazione: (2018)

Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank
di: Nevado-Holgado, A, et al.
Pubblicazione: (2016)

Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and CSF
di: Winchester, L, et al.
Pubblicazione: (2022)

18F-flutemetamol PET/CT imaging in the diagnosis of mild cognitive impairment and Alzheimer's disease：a preliminary study
di: LEI Zhe, et al.
Pubblicazione: (2022-07-01)

Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
di: Milos D. Ikonomovic, et al.
Pubblicazione: (2018-06-01)

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study
di: Hiroshi Matsuda, et al.
Pubblicazione: (2021-01-01)

Blood based proteomic biomarkers of Alzheimer’s disease pathology
di: Alison Louise Baird, et al.
Pubblicazione: (2015-11-01)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
di: Carla M. Startin, et al.
Pubblicazione: (2019-03-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer’s disease
di: Laura M. Winchester, et al.
Pubblicazione: (2018-06-01)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
di: Wesenhagen, KEJ, et al.
Pubblicazione: (2025)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
di: Kirsten E. J. Wesenhagen, et al.
Pubblicazione: (2025-03-01)